Sanofi Aventis is a company operating in the pharmaceutical industry. Created in 2004 from the merger of two European companies, Sanofi Aventis is today the leader in Europe, and is part of the top 5 global companies in its sector.
Sanofi Aventis's self-given mission in the pharmaceutical industry consists in providing a wide portfolio of medicines, in accordance with new pathologies and the behaviors of occidental populations by (increasing age, risky behaviors such as obesity…)
-Developing innovative medicines and answering to changing human needs
-Producing and retailing those medicines.
Sanofi Aventis's product portfolio is based on 7 main therapeutic areas, and several other activities such as generic medicines.
Key information
Key-figures
In term of sales, this French company represented a 27.6 billion € turnover in 2008, and hired nearly 100.000 employees.
b.Products positioning
The activities of company are divided into 7 Strategic activities, and the firm has a strong R&D culture (Research represented more than 17% of turnover of Sanofi Aventis 2008 Budget).
•Central nervous System
•Thrombosis
•Cardio-vascular diseases
•Internal Medicine
•Oncology
•Metabolic diseases
•Vaccination
In term of positioning, Sanofi Aventis retails high added-value products. The new R&D objectives are to progress, on the one hand, for new developed countries diseases (obesity, diabetes, etc.), and on the other hand for new demographic diseases in emerging countries (malaria, Yellow Flu, etc.)
Beyond those traditional activities, the company is currently entering new markets. For example, this year, the company bought Zentiva , a Czech generic producer, with the double objective of producing its own medicine as generics, and targeting new developing countries.
2009 was also the year when Sanofi Aventis began its development on new markets: OTC “over-the-counter” markets, and animal medicines.
c.A short view of Sanofi's corporate culture
Originally, Sanofi Aventis was composed of two main cultures: French and German. However, the company also shares worldwide cultures as the company is present in more than 100 countries all over the world. Anglo-Saxon culture also remains very present in the group, as the American mentality dominates the majority of companies in this domain.
The corporate values of Sanofi Aventis are based on Human relationships, solidarity, progression of humanity, and Ethics. Generally, the staff of Sanofi Aventis is aware of that, and most of the time, it shares those values.
To conclude, the corporate culture of the firm is to offer its employees the possibilities to realize themselves within their work, and the company appears to be a leading company in term of quality of work and motivation in France.
[...] Sources: work cited Drugs Regulator Recommends Suspension Of Sanofi's Acomplia.” Fierce biotech. N.p Oct Web Nov < http: recommends-suspension-sanofis-acomplia>. Persons, Several Persons. Personal & professional interview. July 2009. Sanofi Aventis Annual report 2008. N. pag. Sanofi Aventis Website. Sanofi Aventis Mar Web Nov < http: aventis.com>. Sanofi Aventis “Code Conduct Suppliers.” N. pag. Sanofi Aventis, n.d. Web Nov < http: aventis.com>. “Sanofi Aventis - Debts.” Sanofi Aventis investors website. Sanofi Aventis Sept Web Nov < http: aventis.com>. “Sanofi Aventis détient 94% de Zentiva.” La Tribune 25 Feb. 2009: n. pag. Web Nov [...]
[...] Then, Sanofi Aventis took into consideration that the firm, instead of facing the challenges posed by a large size, was menaced by uncertainty, especially concerning product development and legal management. Thus, this new consideration will also drive the new company strategy for the next years. Recommendations for companies a. Key-success factor requirement The mid-term objectives of Sanofi Aventis are more complex than a simple research for profitability: According to me, the next 10 year of management within Sanofi Aventis should be aimed at improving the security of activity. [...]
[...] Take a position on new kind of medicines for emerging countries. r. Reinforcement of corporate culture Try to standardize international corporate culture, as Sanofi Aventis is a worldwide company. Be an ethical company. Conclusion recommendations for the corporate strategy of Sanofi Aventis Did Sanofi's strategy successfully react to new stakes? Sanofi Aventis's current strategy was designed in order to correspond to stakes between 2001 and today. However, the pharmaceutical market is changing, and the next decade shows new opportunities and threats. [...]
[...] The merging of 2004 Sanofi Aventis is the result of a multiple series of mergers and acquisitions, which ended in 2004 with the final merger between Sanofi- Synthelabo and Aventis. After this merger, external growth operations remained present, but were smaller (ex. Acquisition of Zentiva in 2009, etc.) Part two Environmental analysis of the pharmaceutical industry Pharmaceutical industry: Globally a market under over pressure The pharmaceutical industry is a highly profitable market. At the same time, this market is particularly challenging, as both internal and external environments are acting for or against companies. [...]
[...] After a synthetic approach of Sanofi Aventis in both internal and external aspects, we will try to measure S-A's strategy in order to get to its objectives. To finish, we will try to present a new recommendation to this leading company, in terms of strategy. Part one company overview Presentation of the company Sanofi Aventis is a company operating in the pharmaceutical industry. Created in 2004 from the merger of two European companies, Sanofi Aventis is today the leader in Europe, and is part of the top 5 global companies in its sector. [...]
APA Style reference
For your bibliographyOnline reading
with our online readerContent validated
by our reading committee
